Περίληψη:
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients. © 2017 The Authors
Συγγραφείς:
Zarogoulidis, P.
Chinelis, P.
Athanasiadou, A.
Tsiouda, T.
Trakada, G.
Kallianos, A.
Veletza, L.
Hatzibougias, D.
Mihalopoulou, E.
Goupou, E.
Kosmidis, C.
Sardeli, C.
Huang, H.
Hohenforst-Schmidt, W.
Λέξεις-κλειδιά:
anaplastic lymphoma kinase; carboplatin; epidermal growth factor receptor; gemcitabine; methylprednisolone; nivolumab; paclitaxel; pembrolizumab; programmed death 1 ligand 1; taxane derivative; zoledronic acid, abdominal organ rupture; adult; adverse drug reaction; aged; Article; cancer immunotherapy; cancer patient; cancer therapy; case report; follow up; gene mutation; human; lung adenocarcinoma; male; multiple cycle treatment; neutropenia; non small cell lung cancer; pharmacogenomics; priority journal; squamous cell lung carcinoma
